Advertisement

Topics

Adjuvant nivolumab superior to ipilimumab in surgically resected stage III/IV melanoma

20:00 EDT 10 Sep 2017 | AAAS

(European Society for Medical Oncology) Adjuvant nivolumab is superior to standard of care ipilimumab in patients with surgically resected stage III/IV melanoma who are at high risk of relapse, according to late-breaking results from the CheckMate 238 trial presented today at the ESMO 2017 Congress in Madrid and published in the New England Journal of Medicine. The anti-programmed death-1 (PD-1) antibody nivolumab led to better relapse-free survival, with fewer side effects than ipilimumab.

Original Article: Adjuvant nivolumab superior to ipilimumab in surgically resected stage III/IV melanoma

NEXT ARTICLE

More From BioPortfolio on "Adjuvant nivolumab superior to ipilimumab in surgically resected stage III/IV melanoma"

Quick Search
Advertisement
 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Monoclonal antibodies MAbs
Monoclonal antibodies recognise and attach to specific proteins produced by cells.  Types of monoclonal antibodies used to treat cancer cells: Block cell dividing dividing signals Transport cancer drugs or radiation to cancer cells Tr...

Skin cancers
There are three main types of skin cancer: basal cell carcinoma, squamous cell carcinoma and malignant melanoma. Basal cell carcinoma Basal cell carcinoma, or BCC, is a cancer of the basal cells at the bottom of the epidermis. It’s very common ...